Know Cancer

or
forgot password

Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma)


N/A
N/A
N/A
Not Enrolling
Both
Carcinoma, Renal Cell

Thank you

Trial Information

Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma)


Inclusion Criteria:



- Patients who received Nexavar for unresectable or advanced renal cell carcinoma

Exclusion Criteria:

- Patients who are contraindicated based on the product label

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Incidence of adverse drug reactions and serious adverse events in subjects who received Nexavar

Outcome Time Frame:

After Nexavar administration, up to 1 year

Safety Issue:

Yes

Principal Investigator

Bayer Study Director

Investigator Role:

Study Director

Investigator Affiliation:

Bayer

Authority:

Japan: Ministry of Health, Labor and Welfare

Study ID:

15038

NCT ID:

NCT01411423

Start Date:

April 2008

Completion Date:

March 2012

Related Keywords:

  • Carcinoma, Renal Cell
  • Nexavar
  • Unresectable or advanced renal cell carcinoma
  • Carcinoma
  • Carcinoma, Renal Cell

Name

Location